attention deficit hyperactivity disorder/ニコチン

FIELD OF THE INVENTION The present invention relates to transdermal devices and methods for controllable dispensing of a nutraceutical or an active substance such as a chemical substance, a medication, a drug, a stimulant or the like, to a human or other mammal for purposes of promoting longevity,

FIELD OF THE INVENTION The present invention relates to transdermal devices and methods for controllable dispensing of a nutraceutical or an active substance such as a chemical substance, a medication, a drug, a stimulant or the like, to a human or other mammal for purposes of promoting longevity,

FIELD OF THE INVENTION The present invention relates to transdermal devices and methods for controllable dispensing of a nutraceutical or an active substance such as a chemical substance, a medication, a drug, a stimulant or the like, to a human or other mammal for purposes of promoting longevity,

FIELD OF THE INVENTION The present invention relates to transdermal devices and methods for controllable dispensing of a nutraceutical or an active substance such as a chemical substance, a medication, a drug, a stimulant or the like, to a human or other mammal for purposes of promoting longevity,

FIELD OF THE INVENTION The present invention relates to transdermal devices and methods for controllable dispensing of a nutraceutical or an active substance such as a chemical substance, a medication, a drug, a stimulant or the like, to a human or other mammal for purposes of promoting longevity,

BACKGROUND 1. Field of the Invention The present invention is in the field of pharmacotherapy of nicotine-responsive neuropsychiatric disorders by administering a nicotine antagonist alone, particularly mecamylamine, or in combination with a neuroleptic agent. Examples of such disorders are

CROSS REFERENCE TO RELATED APPLICATIONS This Application claims the benefit of U.S. Provisional Application No. 61/629,387 filed Nov. 16, 2011 and U.S. Provisional Application No. 61/690,461 filed Jun. 27, 2012. STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT (Not

STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT (Not Applicable) REFERENCE TO A SEQUENCE LISTING A TABLE, OR A COMPUTER PROGRAM LISTING APPENDIX SUBMITTED ON A COMPACT DISC (SEE 37 CFR 1.52(e)(5) (Not Applicable) FIELD OF THE INVENTION The present invention relates to novel nicotine

TECHNICAL FIELD The present invention relates in general to a smoking cessation aid, and more particularly to a nicotine containing solution useful as a smoking cessation aid to a user of smoking tobacco, and which is palatably acceptable to the user upon drinking by the user and which provides a

STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT Not applicable REFERENCE TO A "MICROFICHE APPENDIX" Not applicable BACKGROUND On embodiment relates to tobacco products, and more particularly to a tobacco kit product enabling an end user or consumer to prepare a custom tobacco

STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT Not applicable REFERENCE TO A "MICROFICHE APPENDIX" Not applicable BACKGROUND On embodiment relates to tobacco products, and more particularly to a tobacco kit product enabling an end user or consumer to prepare a custom tobacco

STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT Not applicable REFERENCE TO A "MICROFICHE APPENDIX" Not applicable BACKGROUND On embodiment relates to tobacco products, and more particularly to a tobacco kit product enabling an end user or consumer to prepare a custom tobacco

FIELD OF THE INVENTION The present invention relates to new D.sub.3 dopamine receptor subtype selective ligands of formula (I) and/or geometric isomers and/or stereoisomers and/or diastereomers and/or salts and/or hydrates and/or solvates thereof which are useful in the therapy and/or prevention of

FIELD OF THE INVENTION This invention describes new treatments for several nervous system disorders, including: Addictive Disorders, Psychoactive Substance Use Disorders, Nicotine Addiction or Tobacco Addiction resulting in Smoking Cessation and Attention Deficit Hyperactivity Disorder (ADHD). The

FIELD OF THE INVENTION This invention describes new treatments for several nervous system disorders, including: Addictive Disorders, Psychoactive Substance Use Disorders, Nicotine Addiction or Tobacco Addiction resulting in Smoking Cessation and Attention Deficit Hyperactivity Disorder (ADHD). The